Molecular and cytological markers related to the development and prognosis of EB virus-associated lymphoproliferative disorders

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09744
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Dermatology
• Research Institution: Okayama University
• Principal Investigator: IWATSUKI Keiji 岡山大学, 医歯薬学総合研究科, 教授 (80126797)
• Co-Investigator(Kenkyū-buntansha): 三宅 智子 岡山大学, 大学病院, 助教 (30749627) ; 平井 陽至 岡山大学, 大学病院, 助教 (10756068) ; 濱田 利久 岡山大学, 大学病院, 講師 (70346435)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: ＥＢウイルス / T/NKリンパ異常増殖症 / 種痘様水疱症 / 蚊刺過敏症 / 慢性活動性EBV感染症 / ウイルス関連リンパ腫 / 予後因子

Outline of Final Research Achievements

Cutaneous EBV-associated T/NK lymphoproliferative disorders (LPDs) include hydroa vacciniforme (HV) and hypersensitivity to mosquito bites (HMB). We have proposed a clinical spectrum of EBV-associated T/NK LPDs including HV and HMB, and launched guidelines for managements of these disorders. Patients with HV are divided into two groups: a benign subtype designated classic HV (cHV), and more serious systemic HV (sHV). Patients with cHV have increased numbers of EBV-infected gdT cells, and show a favorable prognosis. Patients with sHV are further classified into two groups: gdT-cell- and abT-cell-dominant types. Patients with HMB, with or without HV-like eruptions, have increased numbers of EBV-infected NK cells in the blood. Patients with abT-cell-dominant sHV and HMB have a poor prognosis. In addition to our clinical subtypes and the responsible lymphocyte subsets, the poor prognostic indicators include onset age over 9 years, and the expression of the reactivation marker, BZLF1 mRNA.

Free Research Field

皮膚自己免疫疾患、皮膚リンパ腫、ウイルス性皮膚疾患